m+Medelevator.RU
← Поиск публикаций
RMD open · 2018

Effect of high-intensity interval training on cardiovascular disease risk factors and body composition in psoriatic arthritis: a randomised controlled trial.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Thomsen Ruth Stoklund, Nilsen Tom Ivar Lund, Haugeberg Glenn, Bye Anja, Kavanaugh Arthur, Hoff Mari

Аннотация

BACKGROUND: Psoriatic arthritis (PsA) is associated with an accumulation of cardiovascular disease (CVD) risk factors. The aim of this study was to evaluate the effect of high-intensity interval training (HIIT) on CVD risk factors in patients with PsA.

METHODS: We randomly assigned 61 patients with PsA (41 women and 20 men) to an intervention group performing HIIT for 11 weeks or a control group who were instructed to not change their physical exercise habits. Outcomes were assessed at 3 and 9  months with measures on maximal oxygen uptake (VO2max), fat percentage and Body Mass Index (BMI). We used linear mixed models to calculate mean difference with 95% CI between the groups according to the intention-to-treat principle.

RESULTS: At 3  months, the HIIT group had a 3.72  mL/kg/min (95%  CI 2.38 to 5.06) higher VO2max and a 1.28 (95% CI -2.51 to -0.05) lower truncal fat percentage than controls. There was also some evidence that the HIIT group had lower total fat percentage (-0.80; 95%  CI -1.71 to 0.10) and slightly lower BMI (-0.31; 95%  CI -0.78 to 0.17) than the control group. At 9  months, the HIIT group had still a higher VO2max (3.08; 95%  CI 1.63 to 4.53) than the control group, whereas the difference in other factors were small.

CONCLUSION: In patients with PsA, 3  months with HIIT was associated with a substantial increase in VO2max and a reduction in truncal fat percentage compared with controls. The beneficial effect on VO2max was also sustained through 9  months.

TRIAL REGISTRATION NUMBER: NCT02995460.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты